Aezea (Cenersen) in Combination With Chemotherapy for the Treatment of Acute Myelogenous Leukemia Subjects = 55 Years of Age With No Response to a Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study.

Trial Profile

Aezea (Cenersen) in Combination With Chemotherapy for the Treatment of Acute Myelogenous Leukemia Subjects = 55 Years of Age With No Response to a Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Cenersen (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Eleos
  • Most Recent Events

    • 21 Jul 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database.
    • 21 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2008-002160-34).
    • 13 Oct 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top